Schema-Root.org logo

 

  cross-referenced news and research resources about

 melanoma

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Mon. October 23, 2017

-
Researchers evaluated data from 7629 patients with melanoma included in the North Carolina cancer registry to determine relevant variables ...
Victoria Atkinson, MD, medical oncologist, Princess Alexandra hospital, University of Queensland, discusses the COLUMBUS trial for patients ...

There are 2 BRAF and MEK studies for patients with stage III resected melanoma. The BRIM8 study investigated vemurafenib (Zelboraf) versus ...
In patients with melanoma, the use of intralesional therapies in combination with checkpoint inhibitors has demonstrated to be an improvement ...
Immunotherapy has led a transformation for melanoma care but combinations of anti-PD-1 and CTLA-4 agents are toxic and biomarkers are ...
Intralesional therapies - those delivered directly to the tumor site - used in conjunction with checkpoint inhibitors have shown improvements to ...

According to the report, which was released earlier this year, the region with the highest number of melanoma -- the deadliest form of skin ...
"The ideal timing for melanoma treatment, predominantly surgery, had ... of a pencil eraser)? melanomas are usually bigger than 6 mm when ...
Choosing the Right Therapy for melanoma .... Only the patients with acral lentiginous melanomas and mucosal melanomas are tested for c-KIT ...
The likelihood of a diagnostic change to melanoma increases with the percentage of visible residual pigment of AIMP on the head, neck, hands ...
"Typically, a lot of people assume, wrongly, that melanomas are ... week announced changes to its melanoma diagnosis guidelines for doctors.
skin cancer rates are on the rise with cases of melanoma - the most deadly type ... Their moles turned out to be malignant melanomas, the most ...
As outlined by the melanoma Institute Australia, "the change may be in size, ... "Anecdotally, a lot of melanomas and other types of skin ...
Sarah Lane (34), who lives in Navan, Co Meath, was diagnosed with stage two melanoma in May last year, shortly after the birth of her son, Joe ...
Merrick I. Ross, M.D., discussed key issues in melanoma as the ... have a lot of good systemic therapies for the metastatic uveal melanomas.

Australians are failing to identify the most dangerous kinds of melanomas, according to a revision of guidelines now under way. These pale ...
melanoma that develops from existing moles is likely to be thinner, less ... "The article confirms what we already knew, that more melanomas ...
The Central Coast came into focus for skin care, sun protection and melanoma awareness today as Jay Allen walked from The Entrance to Gosford as part of a ...
Shivani P. Reddy, from the University of Illinois at Chicago College of Medicine, and colleagues assessed the risk of melanoma and hematologic cancers in patients with psoriasis. The researchers found that patients with psoriasis had 1.53 times greater ...
Gina Columbus reports on promising phase III findings in breast cancer and ovarian cancer, a new drug application withdrawn in melanoma, and oncology ...
Insights From: Michael A. Postow, MD, Memorial Sloan Kettering cancer Center; Claire Crowley, RN, Memorial Sloan Kettering Cancer Center; Michael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center; Kellie Gardner, NP, Georgetown ...
NEW YORK - Nivolumab and pembrolizumab exhibited different toxicity profiles and appeared associated with different adverse event frequencies when used as monotherapy for melanoma, according to study results presented at HemOnc Today melanoma ...
The most deadly form of skin cancer kills an estimated 10,000 Americans per year, with the death toll rising each year. Yet there is no consensus in the medical ...
NEW YORK - Robert H.I. Andtbacka, MD, CM, FACS, FRCSC, surgical oncologist at Huntsman cancer Institute, and a HemOnc Today Editorial Board member, discussed the potential role of injectable immunotherapies and how they could change the tumor ...
The illness forced Michelle Purchase, 29, and her husband Ray to get married a year earlier than planned - and she even held a 30th birthday party several ...
Mucosal melanoma is associated with a poorer prognosis than cutaneous melanoma. An estimated 50% to 90% of patients who undergo surgery experience recurrence.
The pivotal study is exploring the combination of the PD-1 inhibitor Keytruda (pembrolizumab) with the first-in-class IDO1 inhibitor epacadostat (INCB024360) in patients with stage 3/4 unresectable or metastatic melanoma (NCT02752074). Six hundred ...
The first-in-class IDO1 inhibitor epacadostat (INCB024360), currently being investigated in combination with the PD-1 inhibitor pembrolizumab (Keytruda), could be an exciting new FDA approval for patients with stage III/IV unresectable or metastatic ...
Screening also may improve the detection of thin, in situ and invasive melanomas. "With [our] large dataset, we hope we can predict the number of people needed to screen by age and sex, and target those more likely to have the thickest melanoma and ...
It is important to remember that surgery remains to be the mainstay treatment of melanoma. If you think about it, surgery has roles in three big groups: management of the primary lesion, management of the nodal disease and management of metastases.
Castle Biosciences' DecisionDx-melanoma gene expression profile (GEP) test is a promising tool to identify melanoma patients at high risk of developing metastatic disease, according to recently presented data from five studies - one from Castle and ...
Turaga: It is important to remember that surgery remains to be the mainstay treatment of melanoma. If you think about it, surgery has roles in 3 big groups: management of the primary lesion, management of the nodal disease, and management of metastases.
The pivotal study is exploring the combination of the PD-1 inhibitor pembrolizumab (Keytruda) with the first-in-class IDO1 inhibitor epacadostat (INCB024360) in patients with stage III/IV unresectable or metastatic melanoma (NCT02752074). Six hundred ...
Success in trials of new drugs for metastatic melanoma propelled the stock of Array Biopharma (Nasdaq:ARRY) 115% in 2016. However, after a string of successes, Array hit a setback earlier this week: It withdrew its first-ever new drug application.
The fiftth annual Elizabeth's Outrun melanoma 5K and Walk will be held on Saturday, May 13 at Enterprise South Nature Park, 190 Still Hollow Loop in Chattanooga.
Decades ago, doctors didn't preach about sun protection, and researchers didn't realize that the sun's ultraviolet rays could cause skin changes that can lead to melanoma, the deadliest form of skin cancer. "The most important reason for the increase ...
Additionally, there are methods under investigation to bridge the gap between targeted therapies and immunotherapy in melanoma. This year, the community could see data from longer follow-up on patients with melanoma who were given a triplet regimen of ...
A study carried out at Retina Consultants of Houston and Houston Methodist hospital confirmed the safety of fine needle aspiration biopsy in patients with uveal melanoma. No tumor cells were found in the scleral tract of the needle or adjacent pars ...
A cancer survivor will speak about her fight against the disease and how to prevent melanoma during a presentation in Huntington in April.
"It is important for dermatologists to know more than only about the skin aspects, because many patients will view their dermatologists as their primary care physician for their melanoma," explained Christopher R. Shea, MD. "It is important to know ...
Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses some of the ongoing adjuvant therapies in development for ...
Array BioPharma has withdrawn its new drug application for binimetinib as a treatment for patients with NRAS-mutant advanced melanoma, based on feedback ...
Insights From: Michael A. Postow, MD, Memorial Sloan Kettering cancer Center; Claire Crowley, RN, Memorial Sloan Kettering Cancer Center; Michael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center; Kellie Gardner, NP, Georgetown ...
According to a team of researchers from the Penn State College of Medicine, there's a new kind of medication that can potentially prevent melanoma from becoming treatment-resistant. It involves a combination of several drugs and is delivered through ...
Jay Allen receives a whole lot of support from the Hastings on his epic fundraising melanoma March.
Investigators are looking into a novel immunotherapy combination that pairs the first-in-class IDO1 inhibitor epacadostat (INCB024360) with the checkpoint blockade agent pembrolizumab (Keytruda) in patients with unresectable or metastatic melanoma.
Each tumour that was removed from Sharon Dei Rocini's brain or lungs would have another in its place within weeks - until she began a revolutionary drug.
Torrential rain and testing weather conditions has not hindered the progress of melanoma Institute Australia's community coordinator Jay Allen on his epic fundraising march.


spacer

 


 


 


 


schema-root.org

   human
    diseases
     cancer
      skin
        melanoma